Dravet syndrome
MONDO:0100135Dravet syndrome is a channelopathy with epilepsy of with onset during the first year of life, typically 4-5 months, characterized by status epilepticus and a variety of drug-resistant seizures often induced by fever, presenting in previously healthy children, and which frequently leads to cognitive and motor impairment. Dravet differs from other channelopathies usually due to a mutation in SCN1A.
Also known as: DS, Dravet, Dravet syndrome, SME, SMEB, myoclonic epilepsy, severe, of infancy, severe myoclonic epilepsy of infancy
52 clinical trials for this condition and its sub-types, 39 tagged with Dravet syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New hope for dravet syndrome: phase 3 trial of EPX-100 aims to cut seizures
Disease control Recruiting nowThis study tests an experimental drug called EPX-100 (clemizole) in 150 children and adults with Dravet syndrome, a severe form of epilepsy. The goal is to see if adding EPX-100 to current treatments can safely reduce the number of motor seizures. Participants will be randomly as…
Phase 3 • Sponsor: Epygenix • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for kids with rare seizure disorder: ION337 trial launches
Disease control Recruiting nowThis study tests a new medicine called ION337 in children aged 2 to 12 with Dravet syndrome, a severe form of epilepsy. The main goal is to see if the drug is safe and tolerable when given as a spinal injection. Researchers will also measure how the drug moves through the body an…
Phase 1/2 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for kids with severe epilepsy: drug trial targets seizures
Disease control Recruiting nowThis Phase 3 study tests a drug called zorevunersen in 170 children aged 2 to 17 with Dravet syndrome, a severe form of epilepsy. The drug is given as an injection into the spine and compared to a sham procedure. The goal is to see if it reduces seizures and improves daily living…
Phase 3 • Sponsor: Stoke Therapeutics, Inc • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Gene therapy trial aims to tame severe childhood epilepsy
Disease control Recruiting nowThis study tests a gene therapy called ETX101 for children with Dravet syndrome, a severe form of epilepsy caused by a genetic change. The treatment uses a harmless virus to deliver a working copy of the gene to help control seizures. The trial includes infants and children up to…
Phase 1/2 • Sponsor: Encoded Therapeutics • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Could a seizure drug also prevent sudden death in dravet syndrome?
Disease control Recruiting nowThis study tests whether the drug Fintepla (fenfluramine) can improve how the brain and lungs respond to carbon dioxide in people with Dravet syndrome, a severe epilepsy. Poor responses to CO2 may increase the risk of sudden unexpected death in epilepsy (SUDEP). Twenty-five parti…
Phase 4 • Sponsor: The University of Texas Health Science Center, Houston • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Gene therapy hopes to tame severe childhood epilepsy
Disease control Recruiting nowThis early-stage trial tests a gene therapy called RC001 in children aged 2 to 18 with Dravet syndrome, a severe form of epilepsy caused by a genetic mutation. The therapy is given as a single injection into the spinal fluid. The main goal is to check safety and how the body proc…
Early phase 1 • Sponsor: Second Affiliated Hospital of Guangzhou Medical University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for babies with severe epilepsy: fenfluramine safety trial launches
Disease control Recruiting nowThis study is testing the safety of fenfluramine, a drug already approved for children 2 and older with Dravet syndrome, in younger children aged 12 to 23 months. Dravet syndrome is a severe genetic epilepsy that starts in the first year of life. The study will enroll 5 children …
Phase 4 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New brain scans aim to uncover why dravet patients face higher sudden death risk
Knowledge-focused Recruiting nowThis study uses PET and MRI scans to look at serotonin pathways in the brainstem of adults with Dravet syndrome, a severe form of epilepsy. Researchers want to see if these pathways are different in Dravet patients compared to those with other drug-resistant epilepsy and healthy …
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Scientists track 1,000 kids with rare epilepsies to uncover better treatments
Knowledge-focused Recruiting nowThis study follows 1,000 children and teens with rare epilepsies (like West and Dravet syndromes) to see how different treatments affect their seizures and thinking skills. Researchers will compare care across hospitals to find what works best. The goal is to give families cleare…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
New study tracks how dravet syndrome changes over time
Knowledge-focused Recruiting nowThis study follows 50 children and young adults with Dravet syndrome caused by SCN1A gene mutations over four years. Researchers will use standard tests to measure changes in thinking, movement, and daily skills. They will also look for chemical markers in the blood that might re…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC